SAN DIEGO (AP) -- Biopharmaceutical company Halozyme Therapeutics Inc. said Thursday that it has named David Ramsay as chief financial officer, replacing Kurt Gustafson.
Ramsay previously served as Halozyme's vice president of corporate development, but he joined the company in 2003 as CFO.
Gustafson had been an executive at Amgen Inc. before he joined Halozyme in 2009. Halozyme said he was leaving the company to pursue other opportunities.
Shares of Halozyme rose 29 cents, or 4 percent, to $7.46 in midday trading. The stock has traded in the 52-week range of $3.86 to $9.92.
- Health Care Industry